Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)

BACKGROUND: VAN remains the standard for MRSA BSI but has been associated with treatment failures and resulted in prolonged BSI durations and recurrences. In vitro studies of VAN/CFZ against MRSA demonstrated synergy and prevention of VAN resistance. However, clinical use of VAN/CFZ has not been rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinh, Trang D, Zasowski, Evan J, Lagnf, Abdalhamid M, Bhatia, Sahil, Dhar, Sorabh, Mynatt, Ryan, Pogue, Jason M, Rybak, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631778/
http://dx.doi.org/10.1093/ofid/ofx163.631

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631778/
http://dx.doi.org/10.1093/ofid/ofx163.631

Ejemplares similares